|
ALEC | Alector, Inc. |
|
|
ALEC | Alector, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 2.14 |
| Leverage | 74.11% |
| Market Cap | $ 162.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -123.4m |
| Margin | -111.76% |
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.